Trial Profile
A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 09 Apr 2014 Pooled pharmacokinetic analysis presented at the 105th Annual Meeting of the American Association for Cancer Research.
- 22 Nov 2013 Status changed from active, no longer recruiting to completed.
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.